PURPOSE: The purpose of our study was to evaluate and compare the survival in prostate cancer (PCa) patients who underwent radical prostatectomy (RP) < and > or = 70 years. METHODS: In a prospective cancer database, 626 patients with PCa underwent RP. Patients were categorised into two groups as follows: <70 years (n = 526, young) and > or = 70 years (n = 100, old). We evaluated the histopathological features as well as the clinical follow-up after RP. The median age was 64.4 years (41.1-80.1 years). The median follow-up was 5.3 years (0.1-15.8 years). The preoperative median prostate-specific antigen (PSA) levels for young and old patients were 8.8 ng/ml (0.4-230.0 ng/ml) and 9.9 ng/ml (0.3-165.0 ng/ml). RESULTS: Serum PSA levels were not different comparing the two groups (P = 0.356). The young and old patients had an organ-confined PCa in 56.3 and 58.0% (P = 0.826). They had well and moderately differentiated tumours in 78.7 and 75.0% of cases and poorly differentiated tumours in 21.3 and 25.0% (P = 0.198). Young and old patients had an ECOG > 1 in 2.3% and 7.0% of cases (P = 0.024). A 10-year PSA-free survival for young and old patients was 51.8 and 57.4% (P = 0.721), 10-year-disease-specific survival was 92.3 and 97.6% (P = 0.342), 10-year metastasis-free survival was 86.9 and 89.7% (P = 0.713), and 10-year-overall-survival was 78.1 and 71.2% (P = 0.565). Besides classical risk factors for adverse outcome on multivariate analysis, such as preoperative PSA-levels, extracapsular extension, tumour grade, and positive margin status, age was not a predictor for PSA-free- (P = 0.407), disease-specific- (P = 0.257), and overall-survival (P = 0.121). CONCLUSIONS: In a well-selected healthy, elderly population survival outcome is not worse than that of younger patients with a follow-up of 5.3 years and curative treatment should be recommended.
PURPOSE: The purpose of our study was to evaluate and compare the survival in prostate cancer (PCa) patients who underwent radical prostatectomy (RP) < and > or = 70 years. METHODS: In a prospective cancer database, 626 patients with PCa underwent RP. Patients were categorised into two groups as follows: <70 years (n = 526, young) and > or = 70 years (n = 100, old). We evaluated the histopathological features as well as the clinical follow-up after RP. The median age was 64.4 years (41.1-80.1 years). The median follow-up was 5.3 years (0.1-15.8 years). The preoperative median prostate-specific antigen (PSA) levels for young and old patients were 8.8 ng/ml (0.4-230.0 ng/ml) and 9.9 ng/ml (0.3-165.0 ng/ml). RESULTS: Serum PSA levels were not different comparing the two groups (P = 0.356). The young and old patients had an organ-confined PCa in 56.3 and 58.0% (P = 0.826). They had well and moderately differentiated tumours in 78.7 and 75.0% of cases and poorly differentiated tumours in 21.3 and 25.0% (P = 0.198). Young and old patients had an ECOG > 1 in 2.3% and 7.0% of cases (P = 0.024). A 10-year PSA-free survival for young and old patients was 51.8 and 57.4% (P = 0.721), 10-year-disease-specific survival was 92.3 and 97.6% (P = 0.342), 10-year metastasis-free survival was 86.9 and 89.7% (P = 0.713), and 10-year-overall-survival was 78.1 and 71.2% (P = 0.565). Besides classical risk factors for adverse outcome on multivariate analysis, such as preoperative PSA-levels, extracapsular extension, tumour grade, and positive margin status, age was not a predictor for PSA-free- (P = 0.407), disease-specific- (P = 0.257), and overall-survival (P = 0.121). CONCLUSIONS: In a well-selected healthy, elderly population survival outcome is not worse than that of younger patients with a follow-up of 5.3 years and curative treatment should be recommended.
Authors: Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson Journal: J Natl Cancer Inst Date: 2008-08-11 Impact factor: 13.506
Authors: Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami Journal: JAMA Date: 2004-06-09 Impact factor: 56.272
Authors: Jae Hyun Ryu; Yun Beom Kim; Tae Young Jung; Sun Il Kim; Seok-Soo Byun; Dong Deuk Kwon; Duk Yoon Kim; Tae Hee Oh; Tag Keun Yoo; Woo Jin Ko Journal: J Korean Med Sci Date: 2016-04-25 Impact factor: 2.153